Alnylam Authorizes $1.0B Share Repurchase Program & Announces CCO Departure

Executive Summary

On November 5, 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) filed a Current Report on Form 8-K disclosing two material corporate events:

1. Board Authorization of a $1.0 Billion Share Repurchase Program (Item 8.01): On November 2, 2026, Alnylam's Board of Directors authorized a new stock repurchase program allowing repurchases of up to $1.0 billion of common stock. Alnylam expects to execute approximately $500 million in repurchases before year-end 2026, with the remaining $500 million planned for 2027.
2. Departure of Chief Commercialization Officer (Item 5.02): On November 4, 2026, the company announced that Tolga Tanguler, Executive Vice President and Chief Commercialization Officer, will depart the company in December 2026.

---

Detailed Event Breakdown

1. Share Repurchase Program ($1.0 Billion)

• Authorized Amount: Up to $1.0 billion of common stock.
• Execution Timeline: The company targets approximately $500 million by the end of 2026, with the remainder projected across 2027.
• Repurchase Methods: Open-market repurchases (including via Rule 10b5-1 plans and Rule 10b-18 safe harbors), privately negotiated transactions, or other lawful structures.
• Terms: The program has no fixed expiration date and does not obligate the company to acquire any specific volume or dollar threshold of shares.

2. Leadership Transition

• Executive: Tolga Tanguler
• Role: Executive Vice President, Chief Commercialization Officer
• Departure Date: December 2026
• Separation Terms: The company and Mr. Tanguler intend to execute a written separation agreement setting forth final departure terms on or before his separation date.

---

Market & Strategic Implications

• Capital Allocation Confidence: A $1.0 billion capital return authorization highlights management and board confidence in Alnylam's balance sheet, liquidity profile, and forward cash generation.
• Commercial Continuity: The departure of the Chief Commercialization Officer introduces an executive transition in commercial operations during a pivotal phase, though the planned separation timeline through December 2026 allows for orderly handover.